Biomedical subjects

H Holl

Publications and source records attributed to H Holl.

10 recordsLinked to original sources

PubMed2003

Growth during early childhood in asthmatic children: relation to inhalation steroid dose and clinical severity score.

BACKGROUND/AIM: While short-term studies reported a growth retardation in children with asthma treated with inhaled steroids, long-term studies described attainment of adult heights within the target height range. In the present work, we describe the growth pattern of children with asthma. METHODS: In 58 children with asthma, we compared the height at age 3 years with the height at a mean age of 7.5 years during a 12-month study period. RESULTS: No differences in growth could be detected within the study year. Children in the lowest tertile but not in other tertiles for asthma severity score and inhaled steroid dose showed a significant decrease in height standard deviation scores from age 3 to age 7.5 years. CONCLUSION: The decrease in height standard deviation scores might be explained by undertreatment or an individual sensitivity to inhaled steroids.

Administration, Inhalation↗

PubMed1998

[Gentamicin administration in newborns: once daily].

OBJECTIVE: To determine the serum levels of gentamicin in newborn on one or two daily doses. DESIGN: Retrospective and subsequently prospective, descriptive. SETTING: Department of Pediatrics of the Deventer Hospital, the Netherlands. METHOD: Gentamicin trough and peak plasma levels were analysed retrospectively in 30 neonates to whom gentamicin 3-4 mg/kg/day in two doses had been administered in 1995. In a subsequent prospective study in 1996, 52 neonates received gentamicin 4 mg/kg/day in one dose. Optimal levels were defined as a trough of < 2 mg/l and a peak of 6-12 mg/l. Levels were determined using a immunoassay. RESULTS: Both groups were similar in gestational age, weight and age at the start of treatment. Both trough and peak plasma levels were not known in all patients. Adequate gentamicin trough levels were seen more often in the 'once daily' group than in the 'twice daily' group, in both the premature (12/14 = 86% versus 3/7 = 43%; p = 0.04) and non-premature (36/37 = 97% versus 18/23 = 78%; p = 0.017) neonates. Peak levels were higher in the 'once daily' group than in the 'twice daily' group, in both the prematures (11/13 = 85% versus 1/7 = 14%; p = 0.002) and non-prematures (25/28 = 89% versus 2/22 = 9%; p < 0.000001). Optimal trough and peak levels were found in 9/13 (69%) of the premature and 24/27 (89%) of the non-premature neonates treated according to the 'once daily' schedule, compared with 0 and 1/22 (5%) respectively in the neonates treated according to the 'twice daily' regimen (p = 0.003 and p < 0.0001, respectively). CONCLUSION: In view of the reported levels and the literature, an initial dose of gentamicin of 4.0 mg/kg/day once a day is advised for neonates.

Anti-Bacterial Agents↗

PubMed1993